Taltz (ixekizumab) / Eli Lilly - LARVOL DELTA

O07 Serious infection risk with systemic treatments for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (PubMed, Br J Dermatol) - "Inclusion criteria were adults who received at least one of the biologics, apremilast or conventional nonbiologics (acitretin, ciclosporin and methotrexate) for ≥ 6 months. All biologics licensed for psoriasis were analysed except for infliximab, which had higher prescription criteria...The certolizumab group had a low mean age of 37.4 years (SD 10.3), the ustekinumab group had a significantly longer median treatment duration of over 4 years (IQR 1.83-6.73), and more patients in the ixekizumab (42.6%) and certolizumab (40.6%) groups had concomitant psoriatic arthritis...IRs (95% CIs) of other tumour necrosis factor-α inhibitors were 15.7 (14.5-17.1) for adalimumab and 16.7 (13.8-20.0) for etanercept. For interleukin-17 inhibitors the IRs (95% CIs) were 18.4 (15.9-21.2) for secukinumab, 7.63 (0.92-27.6) for bimekizumab, 14.5 (7.73-24.8) for brodalumab and 18.5 (14.0-24.0) for ixekizumab. For interleukin-23 inhibitors the IRs (95% CIs) were 13.5 (9.97-17.8) for guselkumab,..."

Journal • Observational data • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

O05 A retrospective review of cases of psoriasis requiring discontinuation of biologic therapy from 2007 to 2024 in a multisite NHS trust. (PubMed, Br J Dermatol) - "Concurrent systemic immunosuppression (methotrexate or ciclosporin) was prescribed in 21% (n = 31)...The biologics with most interventions were adalimumab or biosimilars (n = 102: Humira n = 39, Idacio n = 30, Hyrimoz n = 23, Amgevita n = 10), ustekinumab (n = 39), secukinumab (n = 35), guselkumab (n = 13) and certolizumab (n = 11)...The main blood abnormality was positive tuberculosis ELISpot assay (interferon-γ release assay) (n = 6: Humira n = 2; and Idacio, ustekinumab, etanercept and risankizumab n = 1 each). Other abnormalities included leucocytosis in sepsis (n = 2; ustekinumab, secukinumab), neutropenia (n = 1; Hyrimoz), raised alanine aminotransferase (n = 1; Humira) and raised fetal calprotectin (n = 1; Ixekizumab)...Blood abnormalities requiring treatment intervention were infrequent, most commonly positive tuberculosis testing. Our findings support reducing blood monitoring of..."

Journal • Retrospective data • Atopic Dermatitis • Dermatology • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Neutropenia • Pain • Psoriasis • Psoriatic Arthritis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Septic Shock • Seronegative Spondyloarthropathies • Tuberculosis • Type 2 Diabetes Mellitus • Ulcerative Colitis • Urticaria • IFNG

A Case of Rapidly Progressive Dyspnea and Diffuse Pulmonary Lesions. (PubMed, Chest) - "After administration of ixekizumab therapy, her skin lesions demonstrated significant improvement. She denied any history of tobacco use or chronic lung disease."

Journal • Cough • Dermatology • Immunology • Psoriasis • Pulmonary Disease • Respiratory Diseases • IL17A

What is the optimal sequential therapy after secondary IL-17A inhibitor failure in psoriasis: switching to an IL-23 inhibitor or to another IL-17A inhibitor? (PubMed, J Dermatolog Treat) - "This single-center, retrospective analysis included psoriatic patients who experienced secondary failure to either ixekizumab or secukinumab and subsequently switched to another IL-17A inhibitor (ixekizumab or secukinumab; intraclass switching group) or to an IL-23 inhibitor (guselkumab; interclass switching group). Previous exposure to ≥2 biologics working on different pathways was identified as a risk factor for treatment failure in the interclass switching group. An intraclass switch following IL-17A inhibitors failure yielded better treatment outcomes than a switch to guselkumab."

Journal • Retrospective data • Dermatology • Immunology • Psoriasis • IL17A • IL23A

New Toxicity Signals Associated With Ixekizumab. (PubMed, Ann Pharmacother) - No abstract available

Journal

Comparative effectiveness of ixekizumab versus ustekinumab in patients with psoriasis: an RCT replication using data from an observational study (SPEECH). (PubMed, Value Health) - "The results of IXORA-S were successfully replicated using real-world data from SPEECH. This demonstrates that registry-based observational data can yield reliable estimates of treatment effects and may be used to investigate effectiveness questions not feasible to study in randomized trials, such as long-term outcomes and effects in underrepresented populations."

HEOR • Journal • Observational data • Dermatology • Immunology • Psoriasis

Disseminated herpes simplex virus type 1 treated with ixekizumab in a patient with erythrodermic psoriasis: A case report. (PubMed, World J Clin Cases) - "This case highlights the diagnostic and therapeutic challenges of managing EP in the setting of biologic therapy. Disseminated cutaneous HSV-1 should be considered in immunosuppressed patients presenting with new vesicular eruptions, and prompt PCR testing with early antiviral therapy is essential. A multidisciplinary approach is critical to balance immunosuppression for disease control with infection risk."

Journal • Bipolar Disorder • CNS Disorders • Critical care • Dermatology • Dermatopathology • Eosinophilia • Fibrosis • Gastroenterology • Hematological Disorders • Hepatology • Herpes Simplex • Immunology • Infectious Disease • Liver Cirrhosis • Mood Disorders • Psoriasis • Psychiatry

KLRB1 and IL12RB1 are pretherapeutic predictors of time to relapse in patients of psoriasis treated with IL-17 blockade. (PubMed, J Am Acad Dermatol) - "Patients with psoriasis exhibit elevated level of KLRB1 and IL12RB1 at baseline have a higher risk of relapse after ixekizumab withdrawal."

Journal • Dermatology • Immunology • Psoriasis • CD4 • IL12RB1 • KLRB1

Impact of Biologic Class on Ocular Outcomes in Psoriasis: Insights from a Multi-Institutional Database Study (ISDS 2025) - "Adults aged 18–89 years with psoriasis who initiated either TNFα inhibitors (adalimumab, etanercept, infliximab, certolizumab pegol, golimumab) or IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab) within one year of diagnosis were identified. In this large, multi-institutional analysis, psoriasis patients treated with TNFα inhibitors experienced higher rates of several ocular inflammatory and degenerative conditions compared to those treated with IL-17 inhibitors. These findings highlight the importance of considering ocular comorbidity risk when selecting biologic therapy for psoriasis."

Clinical • Cataract • Conjunctivitis • Dermatology • Dry Eye Disease • Immunology • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Psoriasis • Uveitis • IL17A

Real-World Switching and Discontinuation Patterns for Biologic Disease-Modifying Antirheumatic Drugs in Patients with Active Psoriatic Arthritis in Japan. (PubMed, Mod Rheumatol) - "ResultsIncluded patients received adalimumab (n = 323), brodalumab (n = 71), certolizumab pegol (n = 162), guselkumab (n = 157), ixekizumab (n = 239), risankizumab (n = 117), secukinumab (n = 250), or ustekinumab (n = 60). ConclusionSwitching and discontinuation were common within 1-year of bDMARD treatment for PsA patients in Japan. Risankizumab demonstrated the lowest rates of switching and/or discontinuation."

Journal • Real-world evidence • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

TOGETHER-PsA: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (clinicaltrials.gov) - P3 | N=250 | Active, not recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Aug 2026 ➔ Apr 2026

Trial completion date • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) (clinicaltrials.gov) - P4 | N=200 | Recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Feb 2027 ➔ Nov 2027 | Trial primary completion date: Feb 2027 ➔ Nov 2027

Trial completion date • Trial primary completion date • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) (clinicaltrials.gov) - P4 | N=200 | Recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Oct 2026 ➔ May 2028 | Trial primary completion date: Oct 2026 ➔ May 2028

Trial completion date • Trial primary completion date • Dermatology • Genetic Disorders • Immunology • Obesity • Psoriasis

Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors. (PubMed, Adv Ther) - "This real-world study identified greater on-label treatment persistence rates at 24 months in patients with active PsA initiating guselkumab versus SC IL-17Ai, overall and among biologic-naïve and biologic-experienced subgroups."

Journal • Real-world evidence • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Eruptive Seborrheic Keratoses Following Hpv Vaccination During Ixekizumab Therapy for Psoriasis: A Case Report and Literature Review. (PubMed, Clin Cosmet Investig Dermatol) - "We report the case of a 37-year-old female with psoriasis who, after achieving stable disease control on ixekizumab, developed widespread eruptive brown macules, patches, and papules within one month of receiving a quadrivalent HPV vaccine...The lesions faded following oral acitretin therapy...We discuss potential mechanisms, propose clinical management considerations, and provide insights that may inform future research and clinical practice. The ultimate aim is to contribute to the refinement of guidelines on vaccination in patients receiving biologic therapy for psoriasis, ensuring both therapeutic efficacy and patient safety."

Journal • Dermatology • Immunology • Oncology • Psoriasis • IL17A

Onycho-pachydermo periostitis: Ixekizumab as a therapeutic option. (PubMed, JAAD Case Rep) - No abstract available

Journal • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Systematic Review and Meta-Analysis of the Efficacy and Safety of Biologics in the Treatment of Ankylosing Spondylitis (ISPOR-EU 2025) - "Full data on study characteristics and outcomes related to the efficacy and safety of biologics in AS treatment were extracted. A total of 544 records were initially identified, of which 26 studies were included: 17 studies on TNF-α-inhibitors (etanercept, infliximab, adalimumab, golimumab, certolizumab), 5 studies on IL-17-inhibitors (secukinumab, ixekizumab), and 4 studies on JAK-inhibitors (tofacitinib, upadacitinib). Biologics demonstrated significantly greater clinical efficacy compared to placebo in the treatment of AS, with consistent improvements in BASDAI, ASAS20, and ASAS40. While mortality and SAEs rates were similar across groups which had no significant differences compared to placebo, AEs risks varied by biologic class, being no significant different for JAK-inhibitors and increased for TNF-α and IL-17-inhibitors."

Retrospective data • Review • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Design and methods of the Ixekizumab Diabetes Intervention Trial (I-DIT): protocol for a phase 2, randomised, multicentre, placebo-controlled, double-blind trial of anti-interleukin 17 as a treatment option for adults with new-onset type 1 diabetes. (PubMed, BMJ Open) - P2 | "Results of this study will be submitted for publication in international peer-reviewed journals and key findings will be presented at international scientific conferences. ClinicalTrials.gov, NCT04589325."

Journal • P2 data • Diabetes • Endocrine Disorders • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus • IL17A

Short- and Longer-Term Healthcare Resource Utilization and Related Costs With Psoriasis in Brazilian Private Market (ISPOR-EU 2025) - "Most reimbursed biological drugs were infliximab (41.3%), secukinumab (29.7%), ixekizumab (18.4%) and others (10.6%). This study analyzed the healthcare costs associated with patients diagnosed with psoriasis, highlighting a substantial economic burden that escalates as the disease progresses. Over the past decade, the therapeutic landscape for psoriasis has undergone a significant transformation with the advent of biologic therapies. The benefits are well known, but they come at a very high cost."

HEOR • Dermatology • Immunology • Psoriasis

Patient-Relevant Benefits From Ixekizumab Treatment in Patients With Psoriasis: Data From the German National Psoriasis Registry PsoBest (ISPOR-EU 2025) - "Patients receiving ixekizumab demonstrated considerable clinical improvements and meaningful benefits at each time point, despite high treatment needs at baseline indicating high disease burden."

Clinical • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Real-World Costs per Treatment Sequence and per Responder for Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: Evidence From Three Italian Centers (ISPOR-EU 2025) - "Sensitivity analyses varied the second-line agents in Sequences 1 and 2. The base sequence (adalimumab, brodalumab, guselkumab, ixekizumab) resulted in the lowest cumulative cost per patient at the third year (€17,426), compared to €18,184 in sequence 1 (adalimumab, risankizumab, guselkumab, ixekizumab) and €19,087 in sequence 2 (adalimumab, secukinumab, guselkumab, ixekizumab)...In the sensitivity analysis, the base sequence remained the most cost favorable compared to Sequence 1 (tildrakizumab) and Sequence 2 (ustekinumab) in second line. The results indicate that sequencing strategies have a substantial impact on the cost effectiveness of biologic treatments for psoriasis. The results indicate that sequencing strategies have a substantial impact on the cost effectiveness of biologic treatments for psoriasis. The primary objective confirmed brodalumab as the most economically sustainable strategy across the simulations conducted. These findings may support evidence..."

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

Cost per Responder Analysis of Bimekizumab, a Monoclonal IgG1 Antibody Which Selectively Inhibits Il17f in Addition to Il17a Against Il17a Inhibitors in the Treatment of Axial Spondyloarthritis in Finland (ISPOR-EU 2025) - "Based on published network meta-analysis response rates and drug acquisition costs, bimekizumab demonstrated the lowest cost-per-responder outcome at Week 16 across the axSpA disease spectrum (nr-axSpA and r-axSpA) compared with approved IL-17A inhibitors in Finland, suggesting bimekizumab could be considered a preferred IL-inhibitor for treatment of axSpA."

HEOR • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

Bimekizumab Cost per Responder Analysis Compared to Other Licensed Interleukin Inhibitors at Week 52 for the Treatment of Psoriatic Arthritis: A United Kingdom Perspective (ISPOR-EU 2025) - "Treatments included bimekizumab (BKZ), secukinumab (SEC), ixekizumab (IXE), guselkumab (GUS), ustekinumab (UST), and risankizumab (RIS). Bimekizumab demonstrated the lowest cost per response across all IL inhibitors in both biologic-naïve and biologic-experienced PsA populations. Bimekizumab consistently demonstrated the lowest cost per response for both ACR50 and MDA outcomes across IL inhibitors in biologic-naïve and biologic-experienced PsA populations over a 52-week period, supporting its potential as a cost-effective treatment option in UK clinical practice."

HEOR • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A • IL23A

Efficacy and Safety of Biologics to Treat Adults With Active Radiographic Axial Spondyloarthritis: Systematic Review and Bayesian Network Meta-Analysis (ISPOR-EU 2025) - "OBJECTIVES: To compare efficacy and safety of IL-17 inhibitors in the treatment of adults with active radiographic axial spondyloarthritis (r-AxSpA) over a 16-week period using network meta-analysis (NMA). We conducted systematic literature search in PubMed and Embase in November 2024 to retrieve publications with results of randomized controlled trials (RCTs) evaluating efficacy and safety of IL-17 inhibitors (netakimab, secukinumab, ixekizumab, bimekizumab, brodalumab, xeligekimab, vunakizumab) in adults with active r-AxSpA... Netakimab showed the highest relative efficacy among available IL-17 inhibitors used to treat adults with active r-AxSpA over 16-week horizon and demonstrated a favorable safety profile."

Retrospective data • Review • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

Comprehensive assessment of 5 interleukin inhibitors for the treatment of psoriasis: scientific guidance based on drug selection recommendations for Chinese medical institutions. (PubMed, J Pharm Policy Pract) - "The rankings of composite scores, from highest to lowest, were as follows: ixekizumab with 68.8 points, secukinumab with 65.47 points, ustekinumab with 65.41 points, tildrakizumab with 62.6 points, and guselkumab with 61.64 points, taking into account the results from the 5 dimensions. Until the guideline recommendations, the National Essential Drug List, clinical studies, and many other dimensions of this assessment are updated, ixekizumab, secukinumab, and ustekinumab, which have the top 3 scores, can be used as a priority recommendation for Chinese medical institutions to select interleukin inhibitors and optimise the use of the drug catalog based on the scoring results of this assessment."

Journal • Dermatology • Immunology • Psoriasis